MedTrace Logo

Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.

NCT03015909 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2019-01-03

No results posted yet for this study

Summary

The purpose of this study is to assess the ease of use, preference, and safety after 8 weeks subcutaneous administration of EutropinPen Inj. in patients pretreated with recombinant human growth hormone by reusable device.

Conditions

  • Short Stature, Idiopathic
  • Infant, Small for Gestational Age
  • Growth Hormone Deficiency
  • Chronic Renal Failure
  • Turner Syndrome

Interventions

DRUG

Somatropin

Sponsors & Collaborators

  • LG Life Sciences

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-11
Primary Completion
2017-12-21
Completion
2017-12-21

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03015909 on ClinicalTrials.gov